Announcement of the commencement of Phase II clinical trials in Japan for the ophthalmic treatment agent "ROH-001"
April 17, 2025
ROHTO Pharmaceutical Co., Ltd. (Head office: Osaka, President and Representative Director: Masafumi Sugimoto) is pleased to announce that, together with Tsubota Lab Co., Ltd. (Head office: Shinjuku-ku, Tokyo, President and Representative Director: Kazuo Tsubota, hereinafter referred to as "Tsubota Lab"), we have commenced a domestic Phase II clinical trial (hereinafter referred to as "this trial") for our eye drop product, development code "ROH-001," which aims to suppress the progression of myopia, as a therapeutic drug for the ophthalmic field.
Note
In recent years, with the widespread use of smartphones and increased contact with digital devices, various lifestyle changes have been observed, and myopia among young people has become a serious social issue. Therefore, Tsubota Lab and our company entered into a joint research agreement on October 1, 2020, to develop a drug aimed at suppressing myopia progression, and have been conducting basic research since then. To date, efficacy and safety have been confirmed in the nonclinical phase and in the Phase I trial. Based on these trial results, this trial will evaluate efficacy and safety in myopic patients.
With an eye towards entering the pharmaceutical business, our company is conducting various research projects in the field of ophthalmology. We will continue to provide products and services that are useful in ophthalmic medicine and contribute to people's eye health.
About Tsubota Lab Co., Ltd.
| CEO |
Kazuo Tsubota, President and Representative Director |
| location |
Shinjuku Ward, Tokyo |
| Business details |
Research and development related to the prevention and treatment of myopia, dry eye, presbyopia, and other eye diseases, as well as systemic diseases. |
| URL |
https://tsubota-lab.com/ |